dnaJ Peptide for Relieving Rheumatoid Arthritis
Rheumatoid Arthritis
About this trial
This is an interventional treatment trial for Rheumatoid Arthritis focused on measuring RA, Immune Modulation, Oral Tolerance, Peptide, dnaJ
Eligibility Criteria
Inclusion Criteria: Active rheumatoid arthritis as defined by the revised American College of Rheumatology (ACR) 1987 criteria. Evidence of active disease will be based on at least six swollen or nine tender joints. Diagnosis of rheumatoid arthritis of less than 5 years Reactivity to dnaJ Agree to use acceptable methods of contraception Able to understand and sign informed consent Exclusion Criteria: Patients taking more 7.5 mg of prednisone or disease modifying agents other than hydrochloroquine or sulfasalazine (i.e., gold, penicillamine, azathioprine, cyclophosphamide, methotrexate, cyclosporine, or anti-TNF agents) Serum creatinine greater than 1.5 mg/dl SGOT less than SGPT Alkaline phosphatase greater than 2 times age/sex adjusted normal values Hematocrit of less than 30 Platelets less than 130,000 History of lymphoma Any active malignancy or cancer requiring treatment in the last 5 years, except for nonmelanoma skin cancers and carcinoma of the cervix in situ Medical or psychiatric condition or active serious infection Pregnant or breastfeeding
Sites / Locations
- University of Arizona Health Sciences Center
- University of California, Irvine Medical Center
- Stanford University
- Denver Arthritis Center
- Johns Hopkins University
- Mayo Clinic
- Guthrie Clinic
- Virginia Mason Research Center
Arms of the Study
Arm 1
Arm 2
Placebo Comparator
Active Comparator
A
B
Subjects randomized to arm A received 25mg/day po of placebo
Subjects randomized to Arm B received 25mg/day po of peptide dnaJP1